Robert Dreicer, MD, explains how intensifying treatment through the combination of androgen-deprivation therapy and androgen receptor pathway inhibitors (eg, abiraterone acetate [Zytiga], enzalutamide [Xtandi], and apalutamide [Erleada]) has improved outcomes in patients with metastatic castration-sensitive prostate cancer. Dreicer is deputy director, UVA Cancer Center, director, Solid Tumor Oncology in the Division of Hematology/Oncology, and a professor of medicine and urology, University of Virginia Health System.
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.